Xiaoxi Lin has over 15 years’ experience advising private equity and investment fund clients on their most complex and strategic transactions, including control and leveraged buyouts, growth capital investments and public takeovers.
Xiaoxi is one of the most experienced practitioners in Asia in U.S. public transactions, including take privates, PIPE (private investment in public equity) and SPAC/de-SPAC transactions.
He has significant experience advising both financial sponsors and corporations on M&A transactions, with a particular focus on the technology, healthcare and energy sectors, as well as inbound and outbound investments related to China and the U.S.
Xiaoxi has advised a wide range of financial sponsors across the U.S. and Asia, including Advantage Partners, Bain, Baring Private Equity Asia (now EQT Private Capital Asia), Carlyle, Centurium Capital, China Everbright, CITIC Capital/Trustar Capital, C Capital, Canada Pension Plan Investment Board (CPPIB), DCP, Evenstar Capital, Genesis Capital, GF Capital, GP Investments, Hammer Capital, Hillhouse, KKR, Malaysia’s sovereign wealth fund, Mubadala, Ocean Link, Orchid Asia, PAG, Snow Lake, Thomas H. Lee Partners, TPG and Warburg Pincus.
Xiaoxi studied automation at Tsinghua University in Beijing, and actuarial science at the University of Hong Kong. He holds a Juris Doctor from Georgetown University Law Center. He has also passed all three levels of the chartered financial analyst (CFA) exam. From 2017 to 2021, Xiaoxi was the principal author of the China chapter in The Private Equity Review, an annual publication by Lexology In-Depth (formerly The Law Reviews).
Xiaoxi is fluent in English, Mandarin, Cantonese and Shanghainese.
Next Generation Partner for Private Equity in Hong Kong
The Legal 500 Asia-Pacific 2023–2025
Recommended for Private Equity: Foreign Firms in China (2021–2025) and Hong Kong (2020–2025)
The Legal 500 Asia-Pacific 2020–2025